Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

BCID Study > HIV > Flashcards

HIV Flashcards

1
Q

CDC recommendations for HIV screening

A

CDC: i. Opt-out screening for all patients age 13–64 one time in all health care settings during routine care ii. All people with a diagnosis of, and seeking evaluation of or treatment for, a sexually transmit- ted disease, TB, or hepatitis should be screened for HIV infection. iii. Annual HIV testing is recommended for people with the following risk factors: men who have sex with men (MSM), sex with HIV partner, intravenous drug use/shared needles, and sex workers; MSM and bisexual men may benefit from testing every 3–6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Seroconversion window in HIV

A

Seroconversion window a. Time between HIV infection and detection of HIV antibodies b. Time to form antibodies: Around 20–25 days after HIV infection c. HIV RNA or p24 antigen is present during acute infection (10–20 days after infection)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HIV ARV transporter renal transporter interactions

A

Tenofovir is actively secreted by OAT1 and MRP2. (2) Inhibition of OCT2 (e.g., by dolutegravir or rilpivirine) or MATE1 (e.g., by cobicistat) (A) Dolutegravir and cobicistat inhibit tubular secretion of creatinine without affect- ing glomerular filtration rate (GFR) (increasing SCr concentrations). (B) Reduces metformin elimination (maximal daily dose with dolutegravir is 1000 mg) Dolutegravir inhibits the renal organic cation transporter (OCT2), increasing metformin concentrations by 2-fold.

(3) Inhibition of P-glycoprotein by PIs (especially ritonavir)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Advantages of TAF vs TDF

A

Advantages of tenofovir alafenamide over tenofovir disoproxil fumarate: (1) Less bone mineral density (BMD) loss (2) Significantly fewer GFR changes from baseline and proteinuria; no reports of proxi- mal renal tubulopathy to date (3) GFR is improved when changing from tenofovir disoproxil fumarate to tenofovir alafenamide. (4) Renal dose adjustments: Tenofovir disoproxil fumarate should be avoided in patients with a creatinine clearance (CrCl) less than 60 mL/minute/1.73 m2 at baseline or dose adjusted with a CrCl less than 50 mL/minute/1.73 m2 , whereas tenofovir alafenamide is approved to 15 mL/minute/1.73 m2 .

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

P450 interaction profile of NNRTIs

A

All are substrates of CYP3A4; all but rilpivirine induce CYP3A4; etravir- ine inhibits 2C9, 2C19, and P-glycoprotein.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NNRTI rash characteristics

A

Class effect; more common with older agents (nevirapine and efavirenz); cases of
Stevens-Johnson syndrome and toxic epidermal necrolysis; mild to moderate rashes gen-
erally resolve with continued treatment; if rash with systemic symptoms, NNRTIs should
be discontinue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

NNRTI cardiovascular effects

A

Efavirenz may increase TG and LDL; other NNRTIs do not adversely affect the lipid panel; fat redistribution (lipohypertrophy) occurs with efavirenz regimens.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

PI lipid effects

A

all boosted PIs increase LDL and TG with newer agents (darunavir and ataza- navir) having less hypertriglyceridemia; fat redistribution (lipohypertrophy) reported with PI regimens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PIs and renal effects

A

Renal effects: Atazanavir and lopinavir/ritonavir have a greater incidence of chronic kidney disease; kidney stones have formed on atazanavir and indinavir.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

INSTI metabolism/transport

A

Pharmacokinetics: All are substrates of UGT1A1; elvitegravir is also a substrate of CYP3A4 and is boosted with cobicistat.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

INSTI associated with increased LDL and TG

A

Dyslipidemia: Increased LDL and TG (elvitegravir/cobicistat)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Musculoskeletal adverse effects with INSTI

A

Myopathy: Rare cases of increased creatine phosphokinase, weakness, rhabdomyolysis with raltegravir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Renal effects of INSTIs

A

Changes in SCr (a) Cobicistat and dolutegravir typically increase SCr less than 0.2 mg/dL from baseline within 4 weeks of initiating therapy. (b) Patients receiving cobicistat with SCr changes greater than 0.4 mg/dL should be mon- itored closely and evaluated for renal tubulopathy associated with tenofovir disoproxil fumarate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Modern ART regimens that should be given with food (for absorption/tolerability)

A

Require food for absorption and/or tolerability: PIs, NNRTIs (etravirine; rilpivirine – high- calorie meal: 400+ calories), INSTI (elvitegravir)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Modern ARVs requiring empty stomach for absorption/tolerability

A

Empty stomach for absorption or tolerability: NRTI (didanosine), NNRTI (efavirenz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

NNRTI interactions with antiplatelet/anticoagulants

A

(etravirine and efavirenz) inhibit CYP 2C9 and 2C19 metabolism of other drugs and may reduce the bioactivation of clopidogrel (more evidence with etravirine); INR (inter- national normalized ratio) should be closely monitored while on concomitant warfarin therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

PPI - ART interactions

A

Proton pump inhibitors are contraindicated with rilpivirine (absorption)

Proton pump inhibitors interact with atazanavir absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

ARV agents with highest genetic barriers to resistance

A

(PIs, etravirine, and dolutegravir). These medications have a high genetic barrier to resistance.

19
Q

Transmitted resistance prevalence in naive patients and recommendations for testing before initiation

A

Transmitted resistance prevalence: NNRTIs > NRTIs > PIs > INSTIs (c) Recommended before treatment initiation to guide initial ART regimen selection (d) In acute HIV infection and in pregnancy, treatment should be initiated empirically and modified as needed after results.

20
Q

HIV genotypic resistance testing timing

A

Test should be done while the patient is receiving treatment or within 4 weeks of ART discontinuation (ability to detect resistance during selective pressure). (c) Previous resistance reports should be evaluated as resistance is archived in HIV reser- voirs; absence of resistance to ARV medications on subsequent resistance tests is mislead- ing because resistance will reemerge under selective drug pressure.

21
Q

Monitoring and goals for HIV VL after initiation of ART

A

HIV viral load (suppression is less than 20–75 copies/mL; below lower limits of detection): 2–8 weeks after treatment initiation, every 3–4 months for 2 years of ART; then every 6 months with persistent virologic suppression and CD4 greater than 300 cells/

22
Q

Monitoring for CD4 count after ART

A

mm3 b. CD4 count i. Immunologic response to ART and when OI prophylaxis may be discontinued ii. Every 3–6 months for 2 years of ART; then yearly with suppressed viral load and CD4 greater than 300 cells/mm3

23
Q

HIV regimens for MOST patients

A 
DTG + TAF/FTC
DTG + TDF/FTC
DTG/ABC/3TC
EVG/c/TAF/FTC
EVG/c/TDF/FTC
RAL + TAF/FTC 
RAL + TDF/FTC
24
Q

Alternative treatment regimens for HIV

A 
EFV/TDF/FTC
EFV+ TAF/FTC
RPV/TDF/FTC (HIV <200K &amp; CD4>200)
RPV/TAF/FTC (HIV <200K &amp; CD4>200)
DRV/r + TDF/FTC
DRV/r + TAF/FTC
DRV/c + TDF/FTC
DRV/c + TAF/FTC
ATV/c + TAF/FTC
ATV/c + TDF/FTC
ATV/r + TAF/FTC
ATV/r + TDF/FTC
DRV/r + ABC/3TC
DRV/c + ABC/3TC
ATV/c + ABC/3TC
ATV/r + ABC/3TC
RAL + ABC/3TC
DRV/r + RAL If no TDF/TAF/ABC
LPR/r + 3TC if no TDF/TAF/ABC
25
Q

ARVs to avoid in cardiac patients

A

ARV medications that may worsen cardiac risks i. Abacavir should be avoided or used with caution in patients with high CV risk. ii. Lopinavir/ritonavir and darunavir/ritonavir have increased CV risk in some studies

26
Q

PEP for infants born to HIV-positive mothers

A

the greatest risk of perinatal
transmission is during delivery

 	 	 	 	 (b)	 Zidovudine should be initiated within 6–12 hours of delivery and continued for 4–6 weeks, depending on the infant’s HIV risk.

 	 	 	 	 (c)	 Infants should receive cART prophylaxis regimen in the following high-risk situations:
 	 	 	 	 	 (1)	 HIV-infected mother did not receive ART during pregnancy or intrapartum
 	 	 	 	 	 (2)	 HIV-infected mother only received intrapartum ART
 	 	 	 	 	 (3)	 HIV-infected mother did not have viral suppression near delivery on prescribed therapy
 	 	 	 	 	 (4)	 Maternal HIV status is unknown at the time of delive
27
Q

HIV/HBV co-infection management

A

HBV/HIV-coinfected patients should be treated with two HBV-active agents

28
Q

HIV-HCV coinfection management

A

Treating HIV and HCV concurrently: (1) ART should be initiated in all coinfected patients for immunologic improvement and for reducing HIV-related inflammation and immune activation.

29
Q

HBV/HCV coinfection management in HIV-positive patients

A

Patients should be tested for HBV prior to HCV therapy and those with chronic HBV infection should be treated with NRTIs active against both HBV and HIV prior to starting HCV therapy to prevent reactivation of HBV infection

30
Q

NRTI interactions with HCV DAAs

A

Patients should be tested for HBV prior to HCV therapy and those with chronic HBV infection should be treated with NRTIs active against both HBV and HIV prior to starting HCV therapy to prevent reactivation of HBV infection

31
Q

IRIS incidence in CMV/Crypto/TB/HSV

A

Estimated incidence (a) Cytomegalovirus retinitis – CMV (38%) (b) Cryptococcal meningitis (30%) (c) Mycobacterium tuberculosis (16%) (d) Herpes zoster (12%)

iii. Estimated mortality incidence (a) Cryptococcal meningitis (21%) (b) M. tuberculosis (3%)

32
Q

Management of IRIS

A

Mild to moderate-severe IRIS symptoms: Nonsteroidal anti-inflammatory drug (NSAID) therapy – Not recommended in cryptococcal meningitis

Unremitting symptoms on NSAID therapy: Brief course of glucocorticosteroids (e.g., predni- sone for 2–8 weeks; duration depending on OI).

33
Q

Timing of ART initiation relative to OI treatment for PJP/MAC/Crypto/to our

A

PJP - WITHIN 2 weeks
MAC - AFTER 2 weeks of MAC tx
Crypto - AFTER 2-10 weeks of crypto tax
Todo - WITHIN 2 weeks of toxo tx

34
Q

Preferred RFB dosing with 3a4 interaction

A

(1) Rifabutin (A) PIs – Rifabutin daily dosing at a reduced dose (150 mg); three-times-weekly dos- ing no longer recommended

35
Q

Clarithro - PI interaction

A

(2) Clarithromycin – Increased clarithromycin concentrations but no dose adjustments recommended except those with renal impairment;

36
Q

RFB-TAF interaction

A

Tenofovir alafenamide (P-glycoprotein substrate): Rifabutin: Reduced tenofovir alafenam- ide concentrations; coadministration not recommended

37
Q

Regimens for toxo encephalitis

A

1st-line: pyrimethamine/sulfadiazine/leucovorin

Alternative:

pyrimethamine/clindamycin/leucovorin (must add PCP ppx)

TMP/SMX

Atovaquone + (pyrimethamine or sulfadiazine)

Azithromycin + pyrimethamine/leucovorin

Thx for at least 6 weeks

38
Q

Initiating ART in TB

A

Initiation of ART: (a) CD4 count less than 50 cells/mm3 : ART should be initiated within first 2 weeks of TB treatment

CD4 count of 50 cells/mm3 or greater: ART should be initiated 8–12 weeks after initiation of TB treatment.

TB meningitis: ART should be initiated at least 8 weeks after initiating TB treatment, regardless of CD4 count.

39
Q

Monitoring during PrEP

A

HIV testing should be done at baseline and every 3 months, and renal monitoring should be done every 6 months.

40
Q

PEP in HCWs

A

PEP: Exposed health care workers should receive a three-drug regimen for 4 weeks within 72 hours of exposure.

 1 tenofovir/emtricitabine tablet once daily and  	 	 	 b.	 1 raltegravir tablet twice daily
41
Q

Meningococcal vaccination in HIV

A

Two-dose series of meningococcal ACWY conjugate vaccine; revaccinate q5 years

42
Q

Pneumococcal vaccination in HIV

A

Unvaccinated: PCV13 then PPSV 8 weeks later

Prior PPSV: PCV13 at least 1 year after PPSV

43
Q

PEP for HCWs if source HIV status unknown

A

HIV status of source patient is unknown: a. Rapid HIV testing of the source patient should be used to guide the use of PEP, and PEP should not be delayed awaiting results. b. If the test is negative, PEP may be discontinued, and no further testing is needed. c. Concerns for false-negative results related to seroconversion should not direct therapy unless acute retroviral syndrome is suspected.

BCID Study (30 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions